ArticleGene therapy2006
Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 71 citations in OpenAlex.
- Bioinspired Lipid Nanocarriers for RNA Delivery.ACS bio & med chem Au · 2023Review
- Correlative imaging using super-resolution fluorescence microscopy and soft X-ray tomography at cryogenic temperatures provides a new way to assess virosome solutions for vaccine development.Journal of microscopy · 2021Article
- Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers.Frontiers in chemistry · 2021Review
- Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment.Molecules (Basel, Switzerland) · 2020Review
- Cytochalasin-B-Inducible Nanovesicle Mimics of Natural Extracellular Vesicles That Are Capable of Nucleic Acid Transfer.Micromachines · 2019Article
- Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases.Frontiers in pharmacology · 2019Review
- Article
- Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.International journal of nanomedicine · 2018Article
- Chaperonin-Dendrimer Conjugates for siRNA Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2016Article
- Synthetic biology devices for in vitro and in vivo diagnostics.Proceedings of the National Academy of Sciences of the United States of America · 2015Review
- Sendai F/HN viroplexes for efficient transfection of leukemic T cells.Yonsei medical journal · 2013Article
- Reconstruction of H3N2 influenza virus based virosome in-vitro.Iranian journal of microbiology · 2013Article
- Article
- Bio-inspired, bioengineered and biomimetic drug delivery carriers.Nature reviews. Drug discovery · 2011Review
- Nanomedicine in GI.American journal of physiology. Gastrointestinal and liver physiology · 2011Review
- Article
- Pseudovirions as vehicles for the delivery of siRNA.Pharmaceutical research · 2010Article
- Therapeutic opportunities of small interfering RNA.Fundamental & clinical pharmacology · 2009Review
- Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes.Journal of controlled release : official journal of the Controlled Release Society · 2008Article
- siRNA and the lung: research tool or therapeutic drug?Current opinion in pharmacology · 2008Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Application of RNA interference for in vivo evaluation of gene function or for therapeutic interventions has been hampered by a lack of suitable delivery methods for small interfering RNA (siRNA). Here, we present reconstituted viral envelopes (virosomes) derived from influenza virus as suitable vehicles for in vitro as well as in vivo delivery of siRNAs. Virosomes are vesicles that bear in their membrane the influenza virus spike protein hemagglutinin (HA). This protein mediates binding of native virus to and fusion with cellular target membranes. Accordingly, virosomes with membrane-incorporated HA bind to cells, are taken up by receptor-mediated endocytosis, and fuse with the endosomal membrane to release their contents into the cytoplasm. When complexed to cationic lipids, siRNA was successfully encapsulated in virosomes. Virosomes with encapsulated siRNA fused with target membranes in a pH-dependent manner and delivered the encapsulated siRNA to several cell lines in vitro. Virosome-delivered siRNA markedly downregulated the synthesis of newly induced and constitutively expressed green fluorescent protein. Moreover, intraperitoneal injection of siRNA-loaded virosomes resulted in delivery of the nucleotides to cells in the peritoneal cavity. Our results indicate that virosomes are a promising delivery device for in vivo application, especially where topical administration of siRNA, for example, to the respiratory tract is envisaged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.